Biovec, LLC

Biovec Transfusion, LLC

Lakshman R Sehgal

Jonathan Wong

Shaker Ahmed Mousa

A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.

In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors

Vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors

The present invention relates to methods for removing antiplatelet agents and anticoagulants from a platelet preparation. In one embodiment, the method includes the step of flowing the platelet preparation through a filtering tube comprising a filtering membrane and separating the antiplatelet agents and anticoagulants from the platelet preparation by tangential flow filtration. In another embodiment, the method includes the step of passing the platelet preparation through porous material that specifically binds to the antiplatelet agents and anticoagulants.

Method of filtering platelets to remove antiplatelet and anticoagulant agents

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Platelet preservation package comprising a short to ultra-short acting antiplatelet agent and anticoagulant

The present application relates to a method for removing pathogens from a transfusion grade platelet composition. The method comprises the steps of passing a platelet preparation through a first tangential flow filtration (TFF) device having a TFF filter, and collecting a retentate from the TFF device, wherein the retentate comprises filtered platelets to be used for transfusion. The platelet preparation comprises a platelet activation inhibitor and an anti-coagulant. During the TFF process, a diafiltration solution is added to the retentate to maintain the volume of the platelets.

Methods for removing pathogens from a platelet preparation

A platelet preservation composition is disclosed. The composition comprises a photosensitizer, an inhibitor of platelet activation, and/or an anticoagulant. The preservation composition allows inactivation of pathogens in a platelet preparation while maintaining the functionality of the platelets.

Composition for preserving platelets during photosensitization

Composition for preserving platelets and method of using the same

Method for removing antiplatelet agent and anticoagulant from a platelet composition by diafiltration

The present invention relates to methods for preserving platelet. In one embodiment, the method includes the steps of mixing platelets with a platelet preservation composition to form a platelet preparation, storing the platelet preparation for a desired period of time, and removing the antiplatelet agent and the anticoagulant from the platelet preparation by diafiltration prior to transfusion of the platelets. The platelet preservation composition comprises an effective amount of an antiplatelet agent and an effective amount of an anticoagulant.

The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.

Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases

Composition containing short-to-ultrashort GPIIb/IIIa and factor Xa inhibitors and platelets

Method of extending the shelf life of platelets using a composition comprising a short-to-ultrashort antiplatelet agent and anticoagulant and an oxygen carrier

Growing community of inventors

Monarch Beach, CA, United States of America

Lakshman R Sehgal